RecruitingPhase 4NCT06451913

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))

Studying Lyme disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biocodex
Principal Investigator
Oana BERNARD, MD
Chief Scientific Officer
Intervention
Amoxicillin + Saccharomyces boulardii CNCM I-745(drug)
Enrollment
120 target
Eligibility
18 years · All sexes
Timeline
2025 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06451913 on ClinicalTrials.gov

Other trials for Lyme disease

Additional recruiting or active studies for the same condition.

See all trials for Lyme disease →

← Back to all trials